Following the news that microbiome therapeutics developer Vedanta has completed an extended $45.5m series C round, Paul Jeng, Senior Pharma Analyst at GlobalData, a leading data and analytics company, offers his view:
“The additional funding that Vedanta secured for its series C round will support the company through Phase II clinical development of its microbiome-targeted drug, VE303, for prevention of recurrent C. difficile infections (rCDIs).
“According to GlobalData analysis, the CDI market presents a growing opportunity for companies developing novel therapeutics such as Vedanta, and is projected to exceed $1.6bn by the end of 2026, with over 80% of global sales coming from the US.
“Vedanta is one of several companies currently working to commercialize standardized forms of fecal microbiota transplantation (FMT), an investigational treatment strategy with established clinical efficacy for preventing rCDI.
“VE303 leverages defined bacterial consortia with the convenience of capsule-based oral dosing, reducing the procedural complexity of traditional FMT which typically requires an endoscopic procedure. This formulation may also have more direct regulatory routes to approval given the varying policies regarding donor-derived FMT in the US and Europe.
“However, future commercial potential for VE303 will be closely tied market entry and competition from Seres Therapeutics’ SER-109, an orally administered bacterial spore product in Phase III development for rCDIs in adults. If both products are found to have similar efficacy, uptake may ultimately boil down to differences in pill burden or dosing parameters.”